Literature DB >> 33155793

The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?

Pinar Bulutay1, Pinar Firat1, Emine Handan Zeren2, Suat Erus3, Serhan Tanju3, Mustafa Şükrü Dilege3.   

Abstract

Background/aim: Programmed death ligand-1 (PD-L1) is a predictive marker for immunotherapeutic agents. However, heterogeneous staining of PD-L1 can cause false-negative results. The aim of this study is to evaluate the importance of histological patterns on PD-L1 staining heterogeneity in lung adenocarcinomas (LAC). Materials and methods: PD-L1 immunohistochemistry (IHC) stain was performed to two different tissue cores of 128 LAC cases, and cut-off values are given for grouping the cases according to the percentage of staining (1%-10%, 11%-49%, 50%-100%). Staining rates between cores were compared and analyzed by their histological patterns. Also, the relation of the PD-L1 expression with the clinicopathological characteristics of the cases was analyzed.
Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off. PD-L1 expression was significantly related to the high grade micropapillary and solid patterns of adenocarcinomas (p:0.01). Staining cut-offs were mostly similar between cores (43/50, 86%) (k:0.843). However, 14% of them were positive only in one core (7 of 50). This false negativity was mostly related to the histological patterns.
Conclusion: Our data reveal the heterogeneous staining of PD-L1 expression, also micropapillary and solid patterns show higher rates of PDL expression. Therewithal, these findings also highlight the importance of taking into consideration of histological patterns, when choosing a paraffin block for the PDL1. This work is licensed under a Creative Commons Attribution 4.0 International License.

Entities:  

Keywords:  PD-L1; immunotherapy; lung adenocarcinoma; lung cancer

Year:  2021        PMID: 33155793      PMCID: PMC7991888          DOI: 10.3906/sag-2004-61

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  43 in total

1.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.

Authors:  M Ilie; E Long-Mira; C Bence; C Butori; S Lassalle; L Bouhlel; L Fazzalari; K Zahaf; S Lalvée; K Washetine; J Mouroux; N Vénissac; M Poudenx; J Otto; J C Sabourin; C H Marquette; V Hofman; P Hofman
Journal:  Ann Oncol       Date:  2015-10-19       Impact factor: 32.976

Review 2.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.

Authors:  Christian Blank; Andreas Mackensen
Journal:  Cancer Immunol Immunother       Date:  2006-12-29       Impact factor: 6.968

3.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

4.  Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.

Authors:  Francois Ng Kee Kwong; Ute Laggner; Olivia McKinney; James Croud; Alexandra Rice; Andrew G Nicholson
Journal:  Histopathology       Date:  2018-03-05       Impact factor: 5.087

5.  Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Authors:  R S Herbst; P Baas; J L Perez-Gracia; E Felip; D-W Kim; J-Y Han; J R Molina; J-H Kim; C Dubos Arvis; M-J Ahn; M Majem; M J Fidler; V Surmont; G de Castro; M Garrido; Y Shentu; K Emancipator; A Samkari; E H Jensen; G M Lubiniecki; E B Garon
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976

Review 6.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.

Authors:  Kim C Ohaegbulam; Amer Assal; Eszter Lazar-Molnar; Yu Yao; Xingxing Zang
Journal:  Trends Mol Med       Date:  2014-10-30       Impact factor: 11.951

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Prognostic significance of histologic subtype in pStage I lung adenocarcinoma.

Authors:  Nozomu Motono; Takuma Matsui; Yuichiro Machida; Katsuo Usuda; Hidetaka Uramoto
Journal:  Med Oncol       Date:  2017-04-21       Impact factor: 3.064

Review 9.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

10.  The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.

Authors:  Huijuan Li; Yangyang Xu; Bing Wan; Yong Song; Ping Zhan; Yangbo Hu; Qun Zhang; Fang Zhang; Hongbing Liu; Tianhong Li; Haruhiko Sugimura; Federico Cappuzzo; Dang Lin; Tangfeng Lv
Journal:  Transl Lung Cancer Res       Date:  2019-08
View more
  1 in total

1.  PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis.

Authors:  Xuxia Shen; Yue Wang; Yan Jin; Qiang Zheng; Lei Shen; Ying Chen; Yuan Li
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 3.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.